Overview
Glomerular filtration rate (GFR) is a measure of how well your kidneys are filtering waste from your blood. It's one of the most important indicators of kidney health and is used to assess kidney function, detect kidney disease, and guide treatment decisions. However, normal GFR varies considerably with age, as kidney function naturally declines throughout adulthood.
Understanding your age-specific GFR range helps you recognize whether your kidney function is appropriate for your age or whether early intervention might be warranted. This guide explains how GFR is calculated, how age affects kidney function, and what different GFR results mean.
GFR by Age: Expected Values
Kidney function naturally declines with age at a rate of approximately 1 mL/min/1.73m² per year after age 30. The following table shows typical GFR values by age group in healthy individuals without kidney disease:
| Age Group | Average GFR (mL/min/1.73m²) | Lower Limit (5th percentile) | Clinical Significance |
|---|---|---|---|
| 20–29 years | 116 | 108 | Peak kidney function |
| 30–39 years | 107 | 99 | 1 mL/min decline from twenties |
| 40–49 years | 99 | 91 | Noticeable decline begins |
| 50–59 years | 93 | 85 | Moderate decline continues |
| 60–69 years | 85 | 77 | Significant functional change |
| 70+ years | 75 | 67 | Substantial decline; normal variation increases |
These values are based on large population studies and represent healthy individuals without diabetes, hypertension, or chronic kidney disease. Considerable individual variation exists; some people maintain higher GFR values into their 80s and 90s, while others experience accelerated decline.
Why Age-Adjusted GFR Matters
The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 guidelines emphasize that GFR interpretation must account for age. An eGFR of 60 mL/min/1.73m² may represent normal kidney function for a 75-year-old but could indicate early kidney disease in a 40-year-old. The shift toward age-adjusted interpretation reflects evidence that lower GFR in older adults without proteinuria or other signs of kidney damage does not necessarily predict adverse outcomes.
Chronic Kidney Disease (CKD) Stages
CKD is classified into five stages based on GFR, regardless of age, although clinical management varies by age:
| CKD Stage | GFR (mL/min/1.73m²) | Description | Kidney Function |
|---|---|---|---|
| G1 | ≥90 | Normal or high | Normal kidney function; other evidence of kidney damage may be present |
| G2 | 60–89 | Mildly decreased | Mildly reduced; normal for many healthy older adults |
| G3a | 45–59 | Mildly to moderately decreased | Mild-to-moderate decline; increased monitoring recommended |
| G3b | 30–44 | Moderately to severely decreased | Significant reduction; medication adjustments needed |
| G4 | 15–29 | Severely decreased | Advanced kidney disease; preparation for renal replacement therapy |
| G5 | <15 | Kidney failure | End-stage renal disease (ESRD); dialysis or transplant needed |
The addition of albuminuria markers (A1, A2, A3) further refines risk assessment. A1 (<30 mg/g creatinine) represents normal albuminuria, A2 (30–300 mg/g) represents mild albuminuria, and A3 (>300 mg/g) represents severe albuminuria.
When Low GFR Is Normal vs. When It's Concerning
The distinction between expected age-related decline and pathological kidney disease has become clearer with updated guidelines. A low GFR warrants concern if:
Early Decline in Younger Adults
An eGFR below the age-adjusted lower limit suggests declining kidney function in adults under 60. For a 35-year-old, a GFR of 80 mL/min/1.73m² is low and warrants investigation. For a 65-year-old, the same GFR may be normal.
Rapid Decline
A drop of more than 5 mL/min/1.73m² per year, or a decline of >30% over one year, suggests progressive kidney disease and requires investigation regardless of absolute GFR values.
Presence of Albuminuria
Any level of proteinuria (urinary albumin excretion) combined with lower GFR indicates kidney disease requiring treatment. Even with a GFR in the G2 range (60–89), the presence of significant albuminuria represents Stage 2 CKD with increased risk.
Symptoms or Other Laboratory Abnormalities
High creatinine, elevated potassium, anemia, or hypertension combined with low GFR suggests underlying kidney pathology. Symptoms such as swelling, fatigue, or reduced urine output warrant investigation.
GFR Decline in Otherwise Healthy Older Adults
Even in older adults, rapid decline or decline to very low levels (below 30) indicates underlying kidney disease rather than normal aging and warrants diagnostic evaluation.
What Affects GFR Besides Age
Multiple factors influence GFR independent of age:
Muscle Mass and Body Composition
GFR is normalized to body surface area (BSA) of 1.73 m², accounting for differences in body size. However, the creatinine-based eGFR formula may overestimate function in frail or very obese individuals due to differences in creatinine production relative to muscle mass. Individuals with very low muscle mass (such as elderly, disabled, or sarcopenic people) may have lower creatinine levels and falsely elevated eGFR despite reduced true kidney function.
Diabetes
Diabetes accelerates kidney function decline. The progression from normal GFR to CKD to end-stage renal disease may occur more rapidly in people with poorly controlled diabetes, particularly in combination with hypertension.
Hypertension
Chronically elevated blood pressure damages the delicate filtration structures within the kidney. Hypertension is the second leading cause of CKD after diabetes.
Proteinuria
The presence of protein or albumin in urine indicates kidney damage and is associated with more rapid GFR decline, even in those with preserved GFR.
Medications
Certain medications affect GFR or creatinine levels. ACE inhibitors and angiotensin receptor blockers may temporarily lower GFR by reducing pressure in the glomerulus, but this is a protective effect. NSAIDs, aminoglycosides, and contrast dyes can acutely reduce GFR.
Genetic Factors and Cystatin C as an Alternative Marker
African Americans, Native Americans, and Pacific Islanders have slightly higher serum creatinine levels at the same level of true kidney function due to differences in muscle mass. Race-adjusted eGFR equations are no longer recommended by KDIGO, but clinical awareness of this variation is important. For individuals where creatinine-based estimates may be unreliable, cystatin C offers an important alternative.
Cystatin C is a small protein produced by all nucleated cells at a relatively constant rate and freely filtered by the glomerulus. Unlike creatinine, cystatin C production and excretion are independent of muscle mass, making it a superior GFR marker in individuals with very high or very low muscle mass. Elderly individuals, persons with severe obesity, sarcopenic individuals, and those with extreme athletic conditioning often receive falsely elevated (in low muscle mass) or falsely decreased (in high muscle mass) GFR estimates based on creatinine. The Cystatin C-based eGFR equation, or ideally a combined creatinine-cystatin C equation, provides more accurate kidney function assessment in these populations. KDIGO now recommends reporting cystatin C-based eGFR alongside creatinine-based estimates for all patients, allowing clinicians to identify discordance that prompts further evaluation.
Medication Effects on GFR and Creatinine
Beyond ACE inhibitors and ARBs, multiple medication classes affect GFR or measured serum creatinine. Trimethoprim (an antibiotic) and certain antiretroviral medications inhibit the tubular secretion of creatinine, raising serum creatinine and reducing estimated GFR without reflecting true kidney function decline. Conversely, NSAIDs, aminoglycosides, amphotericin B, and radiocontrast agents can acutely reduce GFR through direct kidney injury. Lithium (used for bipolar disorder) causes chronic kidney disease through interstitial nephropathy; individuals taking lithium require regular GFR monitoring. Individuals taking medications affecting kidney function warrant baseline renal assessment and periodic monitoring to distinguish medication effects from progressive kidney disease.
Dehydration
Acute dehydration increases serum creatinine and reduces measured GFR. GFR may be reassessed after adequate hydration.
Acute Illness
Severe infections, sepsis, or other acute conditions can transiently reduce GFR. Follow-up testing after recovery is important to distinguish acute from chronic changes.
How GFR Is Calculated
GFR is estimated using the serum creatinine level, combined with age, sex, and sometimes race, in a mathematical formula. The most widely used equation is the CKD Epidemiology Collaboration (CKD-EPI) 2021 equation, which provides more accurate estimates than older formulas across all GFR ranges.
The creatinine-based eGFR formula is:
eGFR = 141 × min(Scr/κ, 1)^α × max(Scr/κ, 1)^-1.209 × 0.993^Age × [1.018 if female] × [1.159 if Black]
Where:
- Scr = serum creatinine (mg/dL)
- κ = 0.7 (female) or 0.9 (male)
- α = -0.329 (female) or -0.411 (male)
This formula accounts for sex differences in creatinine production and provides more accurate estimates than previous equations, especially at higher GFR values.
Cystatin C Alternative
An alternative marker, cystatin C, is less dependent on muscle mass and may be more accurate in individuals with very high or very low muscle mass. Some laboratories now report both creatinine-based and cystatin C-based eGFR values.
Frequently Asked Questions
Q: What is a "normal" GFR?
A: Normal GFR depends on age. For younger adults (20–39), GFR typically ranges from 99 to 130 mL/min/1.73m². For adults over 70, a GFR of 60–80 mL/min/1.73m² is normal and expected. Your healthcare provider should interpret your GFR in context of your age.
Q: Does a low GFR always mean kidney disease?
A: Not necessarily. A mildly reduced GFR (Stage G2, 60–89 mL/min/1.73m²) in an older adult without proteinuria or other signs of kidney damage may represent normal aging rather than disease. However, a GFR that declines rapidly, or is accompanied by proteinuria or other abnormalities, warrants investigation.
Q: Can GFR improve or get better?
A: Stable or slowly declining GFR is expected with aging. However, acute GFR decline due to reversible causes (such as dehydration, medication side effects, or acute illness) can improve with treatment. In people with CKD, slowing the rate of decline through blood pressure control, diabetes management, and medication (such as ACE inhibitors or SGLT2 inhibitors) is the goal, rather than reversing it.
Q: Why is my GFR different when tested at different times?
A: GFR varies naturally with hydration status, time of day, and other factors. Variation of ±10–15 mL/min/1.73m² is normal. Larger changes warrant investigation.
Q: How often should my GFR be checked?
A: The KDIGO guidelines recommend checking GFR every 12 months for adults with GFR <60 mL/min/1.73m² or the presence of albuminuria. Those with GFR >60 and no albuminuria need less frequent testing unless they have risk factors such as diabetes or hypertension.
Q: Does exercise improve GFR?
A: Regular aerobic exercise may slow the decline in GFR over time and is recommended for overall cardiovascular and kidney health. However, acute intense exercise can transiently increase creatinine; testing is best done at rest.
Q: What is the difference between creatinine-based and cystatin C-based GFR?
A: Creatinine-based GFR depends on serum creatinine production, which is influenced by muscle mass, age, and sex. Cystatin C is less affected by muscle mass and may provide more accurate estimates in individuals with very high or very low muscle mass. Some laboratories now report both values; discordance between the two suggests reassessment may be needed. Ask your laboratory whether cystatin C-based estimates are available if you have unusual muscle mass.
Q: Can I reverse kidney disease once my GFR declines?
A: True kidney disease is rarely reversed; the goal is to slow progression. However, acute GFR declines from reversible causes (acute kidney injury from dehydration, medication, or infection) can resolve with treatment. In chronic kidney disease, blood pressure control (goal <120 mmHg), management of diabetes or other causes, and potentially medication with ACE inhibitors or SGLT2 inhibitors may slow GFR decline to a rate approaching normal aging.
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. GFR interpretation is complex and must account for age, sex, race, muscle mass, and clinical context. Always consult with a qualified healthcare provider to interpret your GFR results and determine whether treatment is needed. Your nephrologist or primary care physician can assess whether your kidney function is appropriate for your age and individual circumstances.
Sources
- Kidney Disease: Improving Global Outcomes (KDIGO). (2024). Clinical practice guideline for the diagnosis and management of chronic kidney disease. KDIGO.
- Inker, L. A., Eneanya, N. D., Coresh, J., et al. (2021). New creatinine and cystatin C-based equations to estimate GFR without race. New England Journal of Medicine, 385(19), 1737–1749.
- Levey, A. S., Coresh, J., Bolton, K., et al. (2012). K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. American Journal of Kidney Diseases, 39(2 suppl 1), S1–S266.
- Matsushita, K., Selvin, E., & Coresh, J. (2011). Change in estimated GFR associates with coronary heart disease and mortality risk. Journal of the American Society of Nephrology, 20(12), 2617–2627.